Aptose appoints Dr. Bernd R. Seizinger to its Board of Directors, effective Sept. 13, 2022

Aptose Biosciences Inc.

Dr. Seizinger brings >25 years pharma/biotech experience, including VP roles at Bristol-Myers Squibb.
He will receive standard non-management director compensation and a 50,000-share option grant under the 2021 plan.
Board now has seven members; appointment effective immediately.
Seizinger has served as CEO of GPC Biotech and holds board positions at multiple biotech firms.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Bernd R. Seizinger, M.D., Ph.D.

Director

APTOF · Aptose Biosciences Inc.

Effective: 2022-09-13
Filed: September 16, 2022, 7:59 PM ET

On September 13, 2022, Aptose Biosciences Inc. (“we” or the “Company”) appointed Dr. Bernd R. Seizinger, M.D., Ph.D. to its Board of Directors (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Bernd R. Seizinger, M.D., Ph.D. was appointed as Director at Aptose Biosciences Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 13, 2022, Aptose Biosciences Inc. (“we” or the “Company”) appointed Dr. Bernd R. Seizinger, M.D., Ph.D. to its Board of Directors (the “Board”).

View on SEC.gov

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-006126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.